Hum RM, Ho P, Nair N, Jani M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Plant D, Barton A, BRAGGSS collaborators, 2022 Oct 3, Non-Trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis. Rheumatology (Oxford), DOI: 10.1093/rheumatology/keac564 |
Alexander LC Jr, Huebner JL, Cicconetti G, Jordan JM, Renner JB, Doherty M, Wilson AG, Hochberg MC, Loeser R, Kraus VB, 2022 Sep, Tibiofemoral knee osteoarthritis progresses symmetrically by knee compartment in the GOGO cohort. Osteoarthr Cartil Open, DOI: 10.1016/j.ocarto.2022.100288 |
Sutcliffe M, Nair N, Oliver J, Morgan AW, Isaacs JD, Wilson AG, Verstappen SMM, Viatte S, Hyrich KL, Morris AP, Barton A, Plant D, 2022 Nov 28, Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. Rheumatology (Oxford), DOI: 10.1093/rheumatology/keac204 |
Oliver J, Nair N, Orozco G, Smith S, Hyrich KL, Morgan A, Isaacs J, Wilson AG, BRAGGSS, Barton A, Plant D, 2021 May 8, Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. Arthritis Res Ther, DOI: 10.1186/s13075-021-02519-6 |
Donnelly S, Wilson AG, Mannan H, Dix C, Whitehill L, Kroll T, 2021, Correction: (In)Visible illness: A photovoice study of the lived experience of self-managing rheumatoid arthritis. PLoS One, DOI: 10.1371/journal.pone.0250451 |
Nair N, Barton A, Wilson AG, 2021 Apr, Cell-specific epigenetic drivers of pathogenesis in rheumatoid arthritis. Epigenomics, DOI: 10.2217/epi-2020-0380 |
O'Leary D, Wilson AG, MacDermott EJ, Lowry C, Killeen OG, 2021 Mar 25, Variability in phenotype and response to treatment in chronic nonbacterial osteomyelitis; the Irish experience of a national cohort. Pediatr Rheumatol Online J, DOI: 10.1186/s12969-021-00530-4 |
O'Leary D, Killeen OG, Wilson AG, 2021 Mar 17, Genetics of chronic nonbacterial osteomyelitis in the irish population: no significant association with rare FBLIM1 variants. Pediatr Rheumatol Online J, DOI: 10.1186/s12969-021-00533-1 |
Oliver J, Nair N, Orozco G, Smith S, Hyrich KL, Morgan A, Isaacs J, Wilson AG, BRAGGSS, Barton A, Plant D, 2021 Mar 10, Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. Arthritis Res Ther, DOI: 10.1186/s13075-021-02451-9 |
Donnelly S, Wilson AG, Mannan H, Dix C, Whitehill L, Kroll T, 2021, (In)Visible illness: A photovoice study of the lived experience of self-managing rheumatoid arthritis. PLoS One, DOI: 10.1371/journal.pone.0248151 |
Gilani SS, Nair N, Plant D, Hyrich K, Morgan AW, Morris AP, Wilson AG, Isaacs JD, Barton A, Bluett J, BRAGGSS Consortium, 2020 Nov, Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. Pharmacogenomics, DOI: 10.2217/pgs-2020-0043 |
Adeeb F, Dorris ER, Morgan NE, Lawless D, Maqsood A, Ng WL, Killeen O, Cummins EP, Taylor CT, Savic S, Wilson AG, Fraser A, 2021 Mar, A Novel RELA Truncating Mutation in a Familial Behçet's Disease-like Mucocutaneous Ulcerative Condition. Arthritis Rheumatol, DOI: 10.1002/art.41531 |
Donnelly S, Manning M, Mannan H, Wilson AG, Kroll T, 2020 Dec, Renegotiating dimensions of the self: A systematic review and qualitative evidence synthesis of the lived experience of self-managing rheumatoid arthritis. Health Expect, DOI: 10.1111/hex.13122 |
McGauran G, Dorris E, Borza R, Morgan N, Shields DC, Matallanas D, Wilson AG, O'Connell DJ, 2020 Oct, Resolving the Interactome of the Human Macrophage Immunometabolism Regulator (MACIR) with Enhanced Membrane Protein Preparation and Affinity Proteomics. Proteomics, DOI: 10.1002/pmic.202000062 |
Dagliati A, Plant D, Nair N, Jani M, Amico B, Peek N, Morgan AW, Isaacs J, Wilson AG, Hyrich KL, Geifman N, Barton A, BRAGGSS Study Group, 2020 Oct, Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. Arthritis Rheumatol, DOI: 10.1002/art.41379 |
Attur M, Zhou H, Samuels J, Krasnokutsky S, Yau M, Scher JU, Doherty M, Wilson AG, Bencardino J, Hochberg M, Jordan JM, Mitchell B, Kraus VB, Abramson SB, 2020 Mar, Interleukin 1 receptor antagonist (IL1RN) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2019-216055 |
Dorris ER, Linehan E, Trenkmann M, Veale DJ, Fearon U, Wilson AG, 2019 Oct 22, Association of the Rheumatoid Arthritis Severity Variant rs26232 with the Invasive Activity of Synovial Fibroblasts. Cells, DOI: 10.3390/cells8101300 |
Nair N, Wilson AG, 2019 Dec, Can machine learning predict responses to TNF inhibitors? Nat Rev Rheumatol, DOI: 10.1038/s41584-019-0320-9 |
Nair N, Plant D, Verstappen SM, Isaacs JD, Morgan AW, Hyrich KL, Barton A, Wilson AG, MATURA investigators, 2020 Jun 1, Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. Rheumatology (Oxford), DOI: 10.1093/rheumatology/kez411 |
Experton J, Wilson AG, Martin CR, 2020, Low-Voltage Flow-Through Electroporation Membrane and Method. Methods Mol Biol, DOI: 10.1007/978-1-4939-9740-4_5 |
Wilson AG, Sherwin J, Dorris ER, 2019 Nov, Patient and public involvement in biomedical research: training is not a substitute for relationship building. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2019-215595 |
Maccarthy J, Guerin S, Wilson AG, Dorris ER, 2019, Facilitating public and patient involvement in basic and preclinical health research. PLoS One, DOI: 10.1371/journal.pone.0216600 |
Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P, 2019 Aug, Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2018-214877 |
Dorris ER, Tazzyman SJ, Moylett J, Ramamoorthi N, Hackney J, Townsend M, Muthana M, Lewis MJ, Pitzalis C, Wilson AG, 2019 Feb 15, The Autoimmune Susceptibility Gene C5orf30 Regulates Macrophage-Mediated Resolution of Inflammation. J Immunol, DOI: 10.4049/jimmunol.1801155 |
Massey J, Plant D, Hyrich K, Morgan AW, Wilson AG, Spiliopoulou A, Colombo M, McKeigue P, Isaacs J, Cordell H, Pitzalis C, Barton A, BRAGGSS, MATURA Consortium, 2018 Sep, Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. Pharmacogenomics J, DOI: 10.1038/s41397-018-0040-6 |
Daghestani HN, Jordan JM, Renner JB, Doherty M, Wilson AG, Kraus VB, 2017, Serum N-propeptide of collagen IIA (PIIANP) as a marker of radiographic osteoarthritis burden. PLoS One, DOI: 10.1371/journal.pone.0190251 |
Savic S, Mistry A, Wilson AG, Barcenas-Morales G, Doffinger R, Emery P, McGonagle D, 2017, Autoimmune-autoinflammatory rheumatoid arthritis overlaps: a rare but potentially important subgroup of diseases. RMD Open, DOI: 10.1136/rmdopen-2017-000550 |
Nair N, Wilson AG, Barton A, 2017 Sep, DNA methylation as a marker of response in rheumatoid arthritis. Pharmacogenomics, DOI: 10.2217/pgs-2016-0195 |
Chaudhry M, Wilson AG, 2017 Sep, The role of genetic analysis for predicting outcome of rheumatoid arthritis. Expert Rev Mol Diagn, DOI: 10.1080/14737159.2017.1355732 |
Smith SL, Plant D, Eyre S, Hyrich K, Morgan AW, Wilson AG, Isaacs JD, Barton A, 2017 Jun 1, The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatology (Oxford), DOI: 10.1093/rheumatology/kew387 |
Graham HT, Rotroff DM, Marvel SW, Buse JB, Havener TM, Wilson AG, Wagner MJ, Motsinger-Reif AA, ACCORD/ACCORDion Investigators, 2016, Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. Front Genet, DOI: 10.3389/fgene.2016.00138 |
Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A, 2016 Nov, Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. Rheumatology (Oxford), DOI: 10.1093/rheumatology/kew299 |
Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A, BRAGGSS, 2017 Jan, High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2015-208849 |
Smith SL, Plant D, Lee XH, Massey J, Hyrich K, Morgan AW, Wilson AG, Isaacs J, Barton A, 2016 May, Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics, DOI: 10.2217/pgs.16.16 |
Plant D, Webster A, Nair N, Oliver J, Smith SL, Eyre S, Hyrich KL, Wilson AG, Morgan AW, Isaacs JD, Worthington J, Barton A, 2016 Jun, Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. Arthritis Rheumatol, DOI: 10.1002/art.39590 |
Smith SL, Eyre S, Yarwood A, Hyrich K, Morgan AW, Wilson AG, Isaacs J, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate 6, Plant D, Barton A, 2015 Dec 14, Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. Arthritis Res Ther, DOI: 10.1186/s13075-015-0868-y |
Hsu YH, Liu Y, Hannan MT, Maixner W, Smith SB, Diatchenko L, Golightly YM, Menz HB, Kraus VB, Doherty M, Wilson AG, Jordan JM, 2015 Nov, Genome-wide association meta-analyses to identify common genetic variants associated with hallux valgus in Caucasian and African Americans. J Med Genet, DOI: 10.1136/jmedgenet-2015-103142 |
Muthana M, Hawtree S, Wilshaw A, Linehan E, Roberts H, Khetan S, Adeleke G, Wright F, Akil M, Fearon U, Veale D, Ciani B, Wilson AG, 2015 Sep 15, C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. Proc Natl Acad Sci U S A, DOI: 10.1073/pnas.1501947112 |
Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Morgan AW, Wilson AG, Hyrich KL, Isaacs J, Barton A, 2015 Feb 26, Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet, DOI: 10.1016/S0140-6736(15)60363-4 |
Wilson AG, Chan Y, Taylor SS, Arcese P, 2015, Genetic Divergence of an Avian Endemic on the Californian Channel Islands. PLoS One, DOI: 10.1371/journal.pone.0134471 |
Hawtree S, Muthana M, Wilkinson JM, Akil M, Wilson AG, 2015 Oct 1, Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis. Hum Mol Genet, DOI: 10.1093/hmg/ddv258 |
Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators, 2015 May, Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol, DOI: 10.1002/art.39169 |
Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W, Symmons DP, Worthington J, Young A, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Raychaudhuri S, Barton A, 2015 Apr 28, Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA, DOI: 10.1001/jama.2015.3435 |
Montes A, Perez-Pampin E, Navarro-Sarabia F, Moreira V, de la Serna AR, Magallares B, Vasilopoulos Y, Sarafidou T, Fernández-Nebro A, Ordóñez Mdel C, Narváez J, Cañete JD, Marquez A, Pascual-Salcedo D, Joven B, Carreira P, Moreno-Ramos MJ, Caliz R, Ferrer MA, Garcia-Portales R, Blanco FJ, Magro C, Raya E, Valor L, Alegre-Sancho JJ, Balsa A, Martin J, Plant D, Isaacs J, Morgan AW, Barton A, Wilson AG, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Gómez-Reino JJ, Gonzalez A, 2015 Mar 18, Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study. Arthritis Res Ther, DOI: 10.1186/s13075-015-0571-z |
Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Cordingley L, Barton A, BRAGGSS, 2015 Mar, Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford), DOI: 10.1093/rheumatology/keu358 |
Knevel R, de Rooy DP, Saxne T, Lindqvist E, Leijsma MK, Daha NA, Koeleman BP, Tsonaka R, Houwing-Duistermaat JJ, Schonkeren JJ, Toes RE, Huizinga TW, Brouwer E, Wilson AG, van der Helm-van Mil AH, 2014 May 7, A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Res Ther, DOI: 10.1186/ar4558 |
Plant D, Wilson AG, Barton A, 2014 Jun, Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol, DOI: 10.1038/nrrheum.2014.16 |
Orozco G, Viatte S, Bowes J, Martin P, Wilson AG, Morgan AW, Steer S, Wordsworth P, Hocking LJ, UK Rheumatoid Arthritis Genetics Consortium, Wellcome Trust Case Control Consortium, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Consortium, Barton A, Worthington J, Eyre S, 2014 Jan, Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association study. Arthritis Rheumatol, DOI: 10.1002/art.38196 |
Cordingley L, Prajapati R, Plant D, Maskell D, Morgan C, Ali FR, Morgan AW, Wilson AG, Isaacs JD, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Barton A, 2014 Jun, Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis. Arthritis Care Res (Hoboken), DOI: 10.1002/acr.22249 |
Yarwood A, Viatte S, Plant D, Morgan AW, Isaacs J, Wilson AG, Hyrich K, Eyre S, Barton A, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), 2014 May, Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2013-204443 |
Scott IC, Seegobin SD, Steer S, Tan R, Forabosco P, Hinks A, Eyre S, Morgan AW, Wilson AG, Hocking LJ, Wordsworth P, Barton A, Worthington J, Cope AP, Lewis CM, 2013, Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. PLoS Genet, DOI: 10.1371/journal.pgen.1003808 |
Gay S, Wilson AG, 2014 Mar, The emerging role of epigenetics in rheumatic diseases. Rheumatology (Oxford), DOI: 10.1093/rheumatology/ket292 |
McAllister K, Yarwood A, Bowes J, Orozco G, Viatte S, Diogo D, Hocking LJ, Steer S, Wordsworth P, Wilson AG, Morgan AW, UK Rheumatoid Arthritis Genetics Consortium, Rheumatoid Arthritis Consortium International, Kremer JM, Pappas D, Gregersen P, Klareskog L, Plenge R, Barton A, Greenberg J, Worthington J, Eyre S, 2013 Dec, Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data. Arthritis Rheum, DOI: 10.1002/art.38183 |
Krabben A, Wilson AG, de Rooy DP, Zhernakova A, Brouwer E, Lindqvist E, Saxne T, Stoeken G, van Nies JA, Knevel R, Huizinga TW, Toes R, Gregersen PK, van der Helm-van Mil AH, 2013 Dec, Association of genetic variants in the IL4 and IL4R genes with the severity of joint damage in rheumatoid arthritis: a study in seven cohorts. Arthritis Rheum, DOI: 10.1002/art.38141 |
Bluett J, Ibrahim I, Plant D, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, BRAGGSS, Barton A, 2014 Apr, Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Pharmacogenomics J, DOI: 10.1038/tpj.2013.26 |
Teare MD, Knevel R, Morgan MD, Kleszcz A, Emery P, Moore DJ, Conaghan P, Huizinga TW, Morgan AW, van der Helm-van Mil AH, Wilson AG, 2013 Oct, Allele-dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis. Arthritis Rheum, DOI: 10.1002/art.38064 |
Bickel WK, Koffarnus MN, Moody L, Wilson AG, 2014 Jan, The behavioral- and neuro-economic process of temporal discounting: A candidate behavioral marker of addiction. Neuropharmacology, DOI: 10.1016/j.neuropharm.2013.06.013 |
Hawtree S, Muthana M, Wilson AG, 2013 Jun, The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes. Biochem Soc Trans, DOI: 10.1042/BST20130053 |
Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF, 2014 Jun, Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2013-203276 |